StatPearls Publishing (NCBI Bookshelf NBK557593), 2026-01-02: A current pharmacology reference chapter summarising methylene blue's mechanism, approved and off-label indications, dosing and contraindications, including the G6PD limitation.
In the treatment of methemoglobinemia, methylene blue is reduced by NADPH-dependent methemoglobin reductase to leucomethylene blue, which then reduces Fe3+ in methemoglobin back to the ferrous state Fe2+, restoring normal hemoglobin function.
Mechanism of Action section (HTML, no pagination)
StatPearls Publishing (NCBI Bookshelf NBK557593), 2026-01-02: A current pharmacology reference chapter summarising methylene blue's mechanism, approved and off-label indications, dosing and contraindications, including the G6PD limitation. Reference chapter / textbook entry (secondary synthesis, continuously updated). Country: United States. Dose given in the chapter: 1-2 mg/kg IV for acquired methemoglobinemia (consistent with the label). Funder and conflicts: StatPearls declares no conflicts for its authors; see chapter. Comparator: none. Terminology note for the verifier: the chapter (like the label) says 'NADPH-dependent methemoglobin reductase'; the older biochemistry distinguishes the physiological NADH-cytochrome b5 reductase from the NADPH-flavin reductase that methylene blue actually uses (MTJ-06), and the StatPearls wording compresses that distinction. Also filed as MTP-32, MTI-122, MTP-44, MTP-07, MTI-121 (claims C1, C10, C5, C7, C9). Study type: review.
